{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:03:52Z","timestamp":1792854232795,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.berh.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:10:17Z","timestamp":1558609817000},"page":"803-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice"],"prefix":"10.1016","volume":"32","author":[{"given":"Lindsay","family":"Lally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.04.006_bib1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2019.04.006_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2019.04.006_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.04.006_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/art.21160","article-title":"Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease","volume":"53","author":"Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","article-title":"Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study","volume":"20","author":"Cantini","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/35.11.1161","article-title":"A\u00a0prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestaions at onset of disease and at the time of diagnosis","volume":"35","author":"Myklebust","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000100","article-title":"Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review","volume":"1","author":"Mackie","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2019.04.006_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.04.006_bib10","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League against rheumatism\/American College of rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.04.006_bib11","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate by used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"Van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.04.006_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.04.006_bib14","first-page":"395","article-title":"Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids","volume":"26","author":"Cimmino","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","article-title":"Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk","volume":"59","author":"Pulsatelli","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib17","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"A\u00a0prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"60","author":"Lally","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib18","first-page":"506","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Vevauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.04.006_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","article-title":"Large-vessel giant cell arteritis: a cohort study","volume":"54","author":"Muratore","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.04.006_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/sarh.2001.16650","article-title":"Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy","volume":"30","author":"Gonz\u00e1lez-Gay","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib21","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/bjs.7595","article-title":"Importance of specimen length during temporal artery biopsy","volume":"98","author":"Ypsilantis","year":"2011","journal-title":"Br J Surg"},{"key":"10.1016\/j.berh.2019.04.006_bib22","doi-asserted-by":"crossref","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","article-title":"Ultrasound in the diagnosis and management of giant cell arteritis","volume":"57","author":"Schmidt","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.04.006_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20900","article-title":"The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study","volume":"20","author":"Lugmani","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.berh.2019.04.006_bib24","first-page":"1136","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"10","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.04.006_bib25","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/art.23699","article-title":"Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis","volume":"58","author":"Bley","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/574248","article-title":"Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography","volume":"2014","author":"Puppo","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.berh.2019.04.006_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18 F-Fluorodeoxyglucose-Positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib28","first-page":"1484","article-title":"A\u00a0randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.04.006_bib30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","article-title":"Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study","volume":"42","author":"Kermani","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib31","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2019.04.006_bib32","first-page":"495","article-title":"A\u00a0prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.04.006_bib34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"For the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib35","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 111","key":"10.1016\/j.berh.2019.04.006_bib36","first-page":"121","article-title":"Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice","author":"Leon","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.04.006_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A\u00a0randomized double-blind trial of abatacept (CTLA-4Ig_ for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2019.04.006_bib38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib39","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","article-title":"Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica","volume":"40","author":"Gabriel","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"149","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.04.006_bib41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/acr.23320","article-title":"Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population","volume":"70","author":"Shbeeb","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.berh.2019.04.006_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","article-title":"Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database","volume":"38","author":"Albrecht","year":"2018","journal-title":"Rheumatol Int"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:18:07Z","timestamp":1761499087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521694219300609"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.04.006","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}